These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 12810203

  • 1. Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors.
    Lee CT, Genega EM, Hutchinson B, Fearn PA, Kattan MW, Russo P, Reuter VE.
    Urol Oncol; 2003; 21(3):179-84. PubMed ID: 12810203
    [Abstract] [Full Text] [Related]

  • 2. IMPORTANCE OF APOPTOSIS MARKERS (MDM2, BCL-2 AND Bax) IN CONVENTIONAL RENAL CELL CARCINOMA.
    Saker Z, Tsintsadze O, Jiqia I, Managadze L, Chkhotua A.
    Georgian Med News; 2015 Dec; (249):27-33. PubMed ID: 26719546
    [Abstract] [Full Text] [Related]

  • 3. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance.
    Hofmockel G, Wittmann A, Dammrich J, Bassukas ID.
    Anticancer Res; 1996 Dec; 16(6B):3807-11. PubMed ID: 9042262
    [Abstract] [Full Text] [Related]

  • 4. Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?
    Diolombi ML, Cheng L, Argani P, Epstein JI.
    Am J Surg Pathol; 2015 Dec; 39(12):1621-34. PubMed ID: 26426379
    [Abstract] [Full Text] [Related]

  • 5. Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma.
    Sejima T, Miyagawa I.
    Eur Urol; 1999 Dec; 35(3):242-8. PubMed ID: 10072628
    [Abstract] [Full Text] [Related]

  • 6. MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma.
    Mytsyk Y, Borys Y, Tumanovska L, Stroy D, Kucher A, Gazdikova K, Rodrigo L, Kruzliak P, Prosecky R, Urdzik P, Dosenko V.
    Clin Exp Med; 2019 Nov; 19(4):515-524. PubMed ID: 31440867
    [Abstract] [Full Text] [Related]

  • 7. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
    Morgan TM, Mehra R, Tiemeny P, Wolf JS, Wu S, Sangale Z, Brawer M, Stone S, Wu CL, Feldman AS.
    Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
    [Abstract] [Full Text] [Related]

  • 8. Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.
    Mitsui Y, Hirata H, Arichi N, Hiraki M, Yasumoto H, Chang I, Fukuhara S, Yamamura S, Shahryari V, Deng G, Saini S, Majid S, Dahiya R, Tanaka Y, Shiina H.
    Oncotarget; 2015 Apr 20; 6(11):9577-91. PubMed ID: 25797254
    [Abstract] [Full Text] [Related]

  • 9. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
    Petraki CD, Gregorakis AK, Vaslamatzis MM, Papanastasiou PA, Yousef GM, Levesque MA, Diamandis EP.
    Tumour Biol; 2006 Apr 20; 27(1):1-7. PubMed ID: 16340244
    [Abstract] [Full Text] [Related]

  • 10. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
    Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, Bracarda S, Basso U, De Giorgi U, Derosa L, Rizzo M, Ortega C, Massari F, Iacovelli R, Milella M, Di Lorenzo G, Buti S, Cerbone L, Burattini L, Montironi R, Santini D, Falconi M, Cascinu S.
    Ann Surg Oncol; 2015 Apr 20; 22(6):2094-100. PubMed ID: 25472645
    [Abstract] [Full Text] [Related]

  • 11. Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.
    Krejci KG, Blute ML, Cheville JC, Sebo TJ, Lohse CM, Zincke H.
    Urology; 2003 Oct 20; 62(4):641-6. PubMed ID: 14550434
    [Abstract] [Full Text] [Related]

  • 12. Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy.
    Sejima T, Morizane S, Hinata N, Yao A, Isoyama T, Saito M, Takenaka A.
    Urol Int; 2012 Oct 20; 88(3):263-70. PubMed ID: 22398398
    [Abstract] [Full Text] [Related]

  • 13. Expression of adipose differentiation-related protein: a predictor of cancer-specific survival in clear cell renal carcinoma.
    Yao M, Huang Y, Shioi K, Hattori K, Murakami T, Nakaigawa N, Kishida T, Nagashima Y, Kubota Y.
    Clin Cancer Res; 2007 Jan 01; 13(1):152-60. PubMed ID: 17200350
    [Abstract] [Full Text] [Related]

  • 14. Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer.
    Virman JP, Bono P, Luukkaala TH, Sunela KL, Kujala PM, Kellokumpu-Lehtinen PL.
    Clin Genitourin Cancer; 2016 Aug 01; 14(4):e283-9. PubMed ID: 26821530
    [Abstract] [Full Text] [Related]

  • 15. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
    Eckel-Passow JE, Ho TH, Serie DJ, Cheville JC, Houston Thompson R, Costello BA, Dong H, Kwon ED, Leibovich BC, Parker AS.
    Cancer Med; 2020 Feb 01; 9(3):1152-1160. PubMed ID: 31829518
    [Abstract] [Full Text] [Related]

  • 16. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML.
    J Urol; 2005 Nov 01; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
    [Abstract] [Full Text] [Related]

  • 17. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma.
    Uhlman DL, Nguyen PL, Manivel JC, Aeppli D, Resnick JM, Fraley EE, Zhang G, Niehans GA.
    J Natl Cancer Inst; 1994 Oct 05; 86(19):1470-5. PubMed ID: 8089867
    [Abstract] [Full Text] [Related]

  • 18. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy.
    Harada K, Miyake H, Kusuda Y, Fujisawa M.
    BJU Int; 2012 Dec 05; 110(11 Pt C):E1131-7. PubMed ID: 22712620
    [Abstract] [Full Text] [Related]

  • 19. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
    Phuoc NB, Ehara H, Gotoh T, Nakano M, Yokoi S, Deguchi T, Hirose Y.
    Urology; 2007 May 05; 69(5):843-8. PubMed ID: 17482919
    [Abstract] [Full Text] [Related]

  • 20. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
    Rausch S, Schollenberger D, Hennenlotter J, Stühler V, Kruck S, Stenzl A, Bedke J.
    J Cancer Res Clin Oncol; 2019 Jan 05; 145(1):153-163. PubMed ID: 30368665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.